London’s MedCity is working to boost collaboration between businesses in the area and invigorate the UK’s so-called ‘golden triangle’ life sciences cluster, with its three major centres in London, Oxford and Cambridge. LSIPR heard from Eliot Forster, who chairs MedCity, about the initiative.
While London, Oxford and Cambridge have long been centres for innovation in the life sciences, with researchers there discovering penicillin and the structure of DNA, for example, the world around the ‘golden triangle’ with the three cities at its corners is changing.
The life sciences industry has undergone some significant adjustments in recent years. As blockbuster drugs fall off the ‘patent cliff’ and research efforts turn from small molecule therapeutics to biologics, the UK is changing its life sciences strategy so that it may stay competitive globally.
In 2011, the government launched its Strategy for Life Sciences initiative, aimed at making the UK a “world-leading place for life sciences investment” by adopting three key strategies: building a life sciences ecosystem, attracting, developing and rewarding the best talent, and creating incentives to promote healthcare innovation.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at email@example.com
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Med City, golden triangle, patent cliff, Strategy for Life